ECSP18041731A - Derivados Novedosos de Diamino Piridina - Google Patents

Derivados Novedosos de Diamino Piridina

Info

Publication number
ECSP18041731A
ECSP18041731A ECIEPI201841731A ECPI201841731A ECSP18041731A EC SP18041731 A ECSP18041731 A EC SP18041731A EC IEPI201841731 A ECIEPI201841731 A EC IEPI201841731A EC PI201841731 A ECPI201841731 A EC PI201841731A EC SP18041731 A ECSP18041731 A EC SP18041731A
Authority
EC
Ecuador
Prior art keywords
novel derivatives
diamino pyridine
compounds
methods
present
Prior art date
Application number
ECIEPI201841731A
Other languages
English (en)
Inventor
Thoma Gebhard
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP18041731A publication Critical patent/ECSP18041731A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La presente invención describe derivados novedosos de diamino piridina que uestran propiedades de modulación de JAK. La presente invención también se refiere a composiciones farmacéuticas que comprenden estos nuevos compuestos, métodos de uso de dichos compuestos en el tratamiento de diversas enfermedades y trastornos que son susceptibles a la modulación de JAK, y procedimientos para preparar los compuestos descritos más adelante.
ECIEPI201841731A 2015-11-26 2018-05-31 Derivados Novedosos de Diamino Piridina ECSP18041731A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15196542 2015-11-26

Publications (1)

Publication Number Publication Date
ECSP18041731A true ECSP18041731A (es) 2018-06-30

Family

ID=54705130

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201841731A ECSP18041731A (es) 2015-11-26 2018-05-31 Derivados Novedosos de Diamino Piridina

Country Status (35)

Country Link
US (3) US10570096B2 (es)
EP (2) EP3380465B1 (es)
JP (1) JP6634157B2 (es)
KR (1) KR102097878B1 (es)
CN (2) CN112851578A (es)
AU (1) AU2016359438B2 (es)
BR (1) BR112018009540A2 (es)
CA (1) CA3005159A1 (es)
CL (1) CL2018001370A1 (es)
CO (1) CO2018005354A2 (es)
CR (1) CR20180285A (es)
CU (1) CU24506B1 (es)
CY (1) CY1123543T1 (es)
DK (1) DK3380465T3 (es)
DO (1) DOP2018000127A (es)
EA (1) EA035899B1 (es)
EC (1) ECSP18041731A (es)
ES (2) ES2916582T3 (es)
HK (1) HK1253530A1 (es)
HR (1) HRP20201662T1 (es)
HU (1) HUE052345T2 (es)
IL (1) IL259360B (es)
LT (1) LT3380465T (es)
MX (1) MX2018006495A (es)
MY (1) MY195905A (es)
PE (1) PE20181071A1 (es)
PH (1) PH12018501019A1 (es)
PL (2) PL3757097T3 (es)
PT (2) PT3757097T (es)
RS (1) RS60946B1 (es)
RU (2) RU2020124922A (es)
SA (1) SA518391657B1 (es)
SG (1) SG11201803760VA (es)
SI (1) SI3380465T1 (es)
WO (1) WO2017089985A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2916582T3 (es) * 2015-11-26 2022-07-01 Novartis Ag Derivados de diaminopiridina
WO2020144604A1 (en) 2019-01-11 2020-07-16 Novartis Ag Lta4h inhibitors for the treatment of hidradenitis suppurativa
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
EP2091918B1 (en) * 2006-12-08 2014-08-27 Irm Llc Compounds and compositions as protein kinase inhibitors
ES2485040T3 (es) * 2007-03-16 2014-08-12 The Scripps Research Institute Inhibidores de cinasa de adhesión focal
US20110230467A1 (en) * 2008-11-21 2011-09-22 Astellas Pharma Inc. 4,6-diaminonicotinamide compound
MX2011005621A (es) 2008-11-28 2011-06-20 Kowa Co Derivado de piridin-3-carboxiamida.
DK2389372T3 (en) 2009-01-23 2015-12-14 Rigel Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR INHIBITION OF JAK pathway
US8415381B2 (en) * 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
TW201300360A (zh) 2010-11-01 2013-01-01 Portola Pharm Inc 做為ｊａｋ激酶調節劑之菸鹼醯胺
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
CA2883534A1 (en) 2012-10-19 2014-04-24 F. Hoffmann-La Roche Ag Inhibitors of syk
AU2013341185B2 (en) * 2012-11-08 2017-07-13 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNalpha responses
ES2702148T3 (es) 2012-11-08 2019-02-27 Bristol Myers Squibb Co Compuestos heterocíclicos sustituidos con amida útiles como moduladores de il-12, il-23 y/o ifn-alfa
BR112015009850A2 (pt) * 2012-11-08 2017-07-11 Bristol Myers Squibb Co compostos de piridila substituídos por heteroarila úteis como moduladores de quinase
US20140343034A1 (en) 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
JP2015014960A (ja) 2013-07-05 2015-01-22 ソニー株式会社 情報処理装置、および記憶媒体
WO2015061665A1 (en) 2013-10-24 2015-04-30 Abbvie Inc. Jak1 selective inhibitor and uses thereof
WO2016090173A1 (en) 2014-12-03 2016-06-09 Rxi Pharmaceuticals Corporation Methods for the treatment of alopecia areata utilizing gene modulation approaches
ES2916582T3 (es) * 2015-11-26 2022-07-01 Novartis Ag Derivados de diaminopiridina

Also Published As

Publication number Publication date
RU2730007C2 (ru) 2020-08-14
RS60946B1 (sr) 2020-11-30
EP3380465A1 (en) 2018-10-03
PE20181071A1 (es) 2018-07-04
WO2017089985A1 (en) 2017-06-01
CN112851578A (zh) 2021-05-28
PT3757097T (pt) 2022-06-20
RU2020124922A (ru) 2020-08-10
LT3380465T (lt) 2020-11-10
SI3380465T1 (sl) 2020-11-30
EP3380465B1 (en) 2020-08-05
MX2018006495A (es) 2018-08-15
US20220177432A1 (en) 2022-06-09
US11274080B2 (en) 2022-03-15
EP3757097B1 (en) 2022-03-30
CU24506B1 (es) 2021-04-07
BR112018009540A2 (pt) 2018-11-06
ES2829052T3 (es) 2021-05-28
MY195905A (en) 2023-02-27
AU2016359438B2 (en) 2019-05-02
EP3757097A1 (en) 2020-12-30
JP2019503343A (ja) 2019-02-07
HK1253530A1 (zh) 2019-06-21
PH12018501019A1 (en) 2018-12-17
PT3380465T (pt) 2020-10-23
DK3380465T3 (da) 2020-10-26
CY1123543T1 (el) 2022-03-24
CA3005159A1 (en) 2017-06-01
CR20180285A (es) 2018-07-16
DOP2018000127A (es) 2018-10-31
HRP20201662T1 (hr) 2020-12-25
CL2018001370A1 (es) 2018-07-27
US10570096B2 (en) 2020-02-25
US20200140386A1 (en) 2020-05-07
KR20180067681A (ko) 2018-06-20
JP6634157B2 (ja) 2020-01-22
CN108349937B (zh) 2021-02-09
HUE052345T2 (hu) 2021-04-28
CO2018005354A2 (es) 2018-05-31
EA201891258A1 (ru) 2018-10-31
KR102097878B1 (ko) 2020-04-06
PL3380465T3 (pl) 2021-01-25
EA035899B1 (ru) 2020-08-28
CN108349937A (zh) 2018-07-31
SA518391657B1 (ar) 2021-02-22
CU20180044A7 (es) 2018-10-04
IL259360A (en) 2018-07-31
AU2016359438A1 (en) 2018-05-31
SG11201803760VA (en) 2018-06-28
ES2916582T3 (es) 2022-07-01
PL3757097T3 (pl) 2022-07-25
US20180354904A1 (en) 2018-12-13
RU2018122953A3 (es) 2020-01-29
RU2018122953A (ru) 2019-12-26
IL259360B (en) 2021-05-31

Similar Documents

Publication Publication Date Title
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CY1123853T1 (el) Ρυθμιστες nrf2
BR112018073384A2 (pt) polinucleotídeos moduladores
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
DOP2016000295A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
PH12016501898B1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
CY1122227T1 (el) Ρυθμιση δραστικοτητας συμπληρωματος
ECSP18049420A (es) Composiciones novedosas, usos y métodos para hacerlas
EA201691582A1 (ru) Новые фармацевтические препараты
CO2018005315A2 (es) Moduladores de la interacción de sestrina-gator2 y sus usos
CO2019012767A2 (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo
CO2017007325A2 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
CL2019000115A1 (es) Compuestos y métodos para la modulación de smn2.
SV2017005412A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
CY1123543T1 (el) Παραγωγα διαμινοπυριδινης
ECSP16074207A (es) Pirazinas moduladoras de gpr6
EP4219507A3 (en) Thienopyrimidinone nmda receptor modulators and uses thereof
TW201713686A (en) Methods for preparing modified von Willebrand factor
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
CL2016002267A1 (es) Ureas asimétricas p-sustituidas y usos médicos de las mismas
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
BR112017019154A2 (pt) uso de frações isoladas de goma mástica para o tratamento de neuropatia óptica
UY37255A (es) Derivados novedosos de diamino piridina
EA201791388A1 (ru) Общий синтез триоксакарцина dc-45-a2 и получение аналогов триоксакарцина
UY35443A (es) Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina